BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Up 0.8% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical is a biotechnology company focused on developing innovative therapies for rare genetic diseases. The company has a diverse pipeline of products targeting various genetic disorders.

Why is BioMarin Pharmaceutical Inc. going up?

BMRN stock is up 0.8% on May 5, 2026 14:36

• BioMarin Pharmaceutical (BMRN) experienced a strong bullish movement today following the release of its Q1 2026 earnings report and conference call.
• The company reported Q1 revenues of $766 million and raised its full-year revenue guidance, driven by the acquisition of Amicus and strong performance of key therapies.
• Despite falling short of analyst expectations on adjusted EPS for Q1, the market reacted positively to the increased revenue outlook and strategic acquisitions.
• The presentation of new data on the efficacy of Voxzogo in treating achondroplasia also contributed to the positive sentiment surrounding BioMarin Pharmaceutical, showcasing the company's commitment to advancing treatments for rare diseases.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

BioMarin Pharmaceutical Q1 2026 earnings preview

This article provides a Q1 2026 earnings preview for BioMarin Pharmaceutical. It anticipates the upcoming financial results for the company.

https://www.msn.com/en-us/health/other/biomarin-pharmaceutical-q1-2026-earnings-preview/ar-AA22bXJo?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call

BioMarin Pharmaceutical (BMRN) reported Q1 2026 revenues of $766 million and raised its full-year guidance to $3.825-$3.925 billion, driven by the acquisition of Amicus and strong performance of enzyme therapies and Voxogo. The company's immediate focus is on integrating Amicus products to accelerate growth, expecting higher revenues and profitability in the second half of 2026. Key pipeline updates include pivotal data for Voxogo in hypochondroplasia and BMN401 for ENPP1 deficiency, both expected in Q2 2026.

https://www.benzinga.com/insights/news/26/05/52269525/transcript-biomarin-pharmaceutical-q1-2026-earnings-conference-call

Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91

BioMarin Pharmaceutical Inc. (BMRN) reported Q1 adjusted EPS of $0.76 per share, falling short of the FactSet estimate of $0.91 per share. This financial update indicates underperformance compared to analyst expectations for the quarter. The company also recently provided its full-year 2026 guidance for revenue and adjusted EPS.

https://www.marketscreener.com/news/earnings-flash-bmrn-biomarin-pharmaceutical-inc-posts-q1-adjusted-eps-0-76-per-share-vs-factse-ce7f58dfdb81f721

BioMarin (NASDAQ: BMRN) raises 2026 sales view following Amicus deal

BioMarin Pharmaceutical Inc. reported its first-quarter 2026 results and significantly raised its full-year 2026 revenue outlook due to the Amicus acquisition, which added GALAFOLD and POMBILITI + OPFOLDA to its portfolio. While total revenues increased by 3% year-over-year, GAAP and Non-GAAP net income decreased due to higher operating and manufacturing costs, including a $31 million NAGLAZYME charge. The company now expects 2026 total revenue between $3.825–$3.925 billion but slightly lowered its Non-GAAP diluted EPS guidance to $4.85–$5.05.

https://www.stocktitan.net/sec-filings/BMRN/8-k-biomarin-pharmaceutical-inc-reports-material-event-b580ad69846f.html

Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia

BioMarin Pharmaceutical Inc. has released new data regarding the long-term impact of its drug, Voxzogo (vosoritide), on children suffering from achondroplasia. The study focuses on how the treatment affects arm span, overall bone health, and growth development in these children. More detailed information requires registration on the MarketScreener website.

https://www.marketscreener.com/news/biomarin-presents-new-data-on-the-effect-of-long-term-treatment-with-voxzogo-vosoritide-on-arm-sp-ce7f58ded88ef427

Trending Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 6.2% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.9% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 6.6% Today

Blink Charging Co. ($BLNK) Stock Forecast: Up 5.1% Today

QuantumScape Corp. ($QS) Stock Forecast: Up 5.9% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 5.5% Today

Unity Software ($U) Stock Forecast: Down 5.4% Today

Cronos Group Inc. ($CRON) Stock Forecast: Down 5.6% Today

Fastly Inc. ($FSLY) Stock Forecast: Down 5.8% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

15.11.2025 - BMRN Stock was down 2.1%

• Hudson Bay Capital Management LP, Bellevue Group AG, and other institutional investors have decreased their stakes in BioMarin Pharmaceutical Inc., possibly indicating concerns about the company's immediate performance outlook.
• Despite falling short of quarterly earnings per share (EPS) estimates, BioMarin's positive guidance for FY2025 and ongoing restructuring efforts have generated optimism among investors. This is evidenced by increased holdings from Dodge & Cox, Viking Global, AQR, Geode, Norges Bank, and Boone Capital Management LLC.
• The market's response to the mixed signals of underperforming earnings but promising future projections implies that investors are considering the company's current obstacles against its growth potential and margin expansion through restructuring and late-stage trials.
• The fluctuation in BioMarin's stock price today results from a combination of short-term profit-taking by some investors and long-term confidence stemming from the company's strategic initiatives and advancements in its pipeline.

24.01.2026 - BMRN Stock was down 5.5%

• BioMarin posted strong Q4 revenue surpassing forecasts and a positive full-year 2025 performance. However, the stock witnessed a bearish trend possibly due to falling short of analyst predictions on non-GAAP EPS and adjusted EBITDA.
• The FDA's rejection of BioMarin's gene therapy for hemophilia A, delaying its potential market launch, might have impacted the negative investor sentiment on the company's future revenue prospects.
• An AI analysis indicating a bleak long-term outlook and increased downside risk for BioMarin could have also influenced the downward pressure on the stock.
• In conclusion, the combination of financial performance lagging expectations and regulatory obstacles could have contributed to the bearish movement of BioMarin's stock today.

18.02.2026 - BMRN Stock was down 5.4%

• The halt of mid-stage trials for the bone disorder treatment, Voxzogo, due to safety concerns like hip joint slippage in patients, led to a 4% drop in BioMarin's shares.
• The discontinuation of dosing and enrollment in Phase 2 trials for Voxzogo targeting various disorders due to slipped capital femoral epiphysis (SCFE) events introduced uncertainty and negatively impacted the stock.
• The competition in the achondroplasia indication, with the FDA approval of Ascendis Pharma's Yuviwel, added pressure on BioMarin as it halted studies for certain disorders, affecting investor confidence and contributing to the bearish movement.
• Despite being considered a compelling value investment opportunity with strong financial health and profitability metrics, the negative developments in the Voxzogo trials overshadowed the potential growth prospects, resulting in the stock's decline.

19.01.2026 - BMRN Stock was up 5.1%

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

27.01.2026 - BMRN Stock was up 5.2%

• Concerns may have initially arisen from the EVP's stock sale, but investors did not seem discouraged by this insider activity.
• The decision to halt the hemophilia gene therapy, Roctavian, due to underwhelming sales could have been seen as a strategic choice to minimize losses and focus on more promising ventures.
• BioMarin's increased efforts in business development amidst rising competition for Voxzogo could have raised investors' optimism about the company's ability to navigate challenges and stay competitive.
• Participation in upcoming investor conferences and a positive Q4 earnings report, surpassing expectations in both earnings and revenue, likely played a role in boosting the positive sentiment surrounding BioMarin's stock today.

10.01.2026 - BMRN Stock was up 5.0%

• BMRN saw an upward trend today following positive analyst ratings and price target increases from various firms, including Piper Sandler, Barclays, and Canaccord Genuity.
• Factors such as the impending acquisition of Amicus Therapeutics and the upcoming data release for its experimental therapy INZ-701 have contributed to the positive outlook surrounding BMRN.
• Analysts view BMRN as undervalued with significant growth potential, anticipating revenue escalation and profit margin enhancement in the coming years.
• The company's strategic acquisitions and dedication to rare disease treatments have bolstered investor confidence, driving the bullish market performance.

12.01.2026 - BMRN Stock was up 1.1%

• Despite anticipated Q4 earnings decline, BioMarin Pharmaceutical (BMRN) saw an upward trend, reflecting investor confidence in its long-term prospects.
• Favorable ratings from analysts, adjustments in price targets, and excitement surrounding the impending acquisition of Amicus Therapeutics have contributed to the positive outlook for BMRN.
• The upcoming crucial data release for the experimental therapy INZ-701, designed for treating ENPP1 Deficiency, stands as a significant driver for BioMarin's presence in the rare disease market and likely heightened investor confidence.
• The generally optimistic sentiment towards BMRN, supported by promising forecasts, analyst support, and forthcoming catalysts, has outweighed worries about the projected earnings decline for the quarter.

05.04.2026 - BMRN Stock was up 0.8%

• BioMarin Pharmaceutical (BMRN) experienced a strong bullish movement today following the release of its Q1 2026 earnings report and conference call.
• The company reported Q1 revenues of $766 million and raised its full-year revenue guidance, driven by the acquisition of Amicus and strong performance of key therapies.
• Despite falling short of analyst expectations on adjusted EPS for Q1, the market reacted positively to the increased revenue outlook and strategic acquisitions.
• The presentation of new data on the efficacy of Voxzogo in treating achondroplasia also contributed to the positive sentiment surrounding BioMarin Pharmaceutical, showcasing the company's commitment to advancing treatments for rare diseases.